Treatment of genotype 4 patients;Tratamiento de pacientes genotipo 4

Gastroenterologia y Hepatologia

Volumn 29, Issue SUPPL. 2, 2006, Pages 146-149

  Diago Madrid, M ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; EUROPE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INCIDENCE; MONOTHERAPY; PREVALENCE; TREATMENT OUTCOME;

EID: 34547878036     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1157/13097649     Document Type: Conference Paper

References (12)

1. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-82.
2. Manns MP, McHutchison JG, Gordon SC, Rutsgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa 2b plus ribavirin compared with interferon alfa 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-65.
3. Castera L, Morice Y, Grando V, Bon C, Deny P, Roulot D. Le virus de l'hepatite C de génotype 4. Caracteristiques épidemiologiques et réponse aux traitments antiviraux. Gastroent Clin Biol. 2003;27: 596-604.
4. Abdo A, Lee S. Management of hepatitis C virus genotype 4. J Gastroenterol Hepatol. 2004;19:1233-9.
5. Halfon P, Neumann AU, Bourliere M, Rieu A, Chadapaud S, Khirl H, et al. Slow viral dynamics of hepatitis C virus genotype 4. J Viral Hepat. 2003;10:351-3.
6. Hasan F, Asker H, Al-Khaldi J, Siddique I, Al-Ajmi M, Owaid S, et al. Peginterferon alfa 2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroent. 2004;99:1733-7.
7. Diago M, Hassanein T, Rodés J, Ackrill A, Sedarati F. Optimized virological response in hepatitis C virus genotype 4 with peginterfron alpha 2a and ribavirin. Ann Intern Med. 2004;140:72-3.
8. Khuroo M, Khuroo M, Dahab S. Meta- analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment Pharmacol. 2004;20:931-8.
9. Diago M, Planas R, Solá R, Boadas J, Del Olmo JA, Crespo J, et al. Estudio piloto de eficacia y seguridad del tratamiento con interferón alfa 2a pegilado asociado a ribavirina en pacientes con hepatitis crónica C genotipo 4: resultados preliminares. Gastroenterol Hepatol. 2006;29(Supl 1):152.
10. Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakan SA, et al. Peginterferon alfa 2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut. 2005;54:858-66.
11. Soriano V, Núñez M, Sánchez Conde M, Barreiro P, García Samaniego J, Martín Carbonero L, et al. Response to interferon based therapies in HIV infected patients with chronic hepatitis C due to genotype 4. Antivir Ther. 2005;10:167-70.
12. Torriani FJ, Rodríguez Torres M, Rockstroh JK, Lissen E, González García J, Lazzarin A, et al. Peginterferon alfa 2a plus ribavirin, for chronic hepatitis C in HIV infected patients: a randomized controlled trial. N Engl J Med. 2004;351:438-50.